Glimivex-M 1 Tablet SR is a combination oral antihyperglycemic agent containing Glimepiride 1mg and Metformin 500mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, functions by stimulating pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The sustained-release formulation ensures a gradual and consistent release of active ingredients, minimizing gastrointestinal side effects commonly associated with Metformin and improving patient compliance through once-daily dosing. Glimivex-M 1 is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on either monotherapy or lifestyle modifications alone. It is essential to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with Metformin. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to components. Dose adjustments may be required based on glycemic response and tolerability. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and guide treatment modifications.